Atezolizumab-based combination gets first line approval for metastatic NSCLC
By Michael Woodhead
12 Jul 2019
The TGA has approved atezolizumab (Tecentriq) in combination with bevacizumab (Avastin), and chemotherapy (paclitaxel and carboplatin), for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC). The immunotherapy-chemotherapy combination is indicated for patients with EGFR mutant or ALK-positive NSCLC, after failure of appropriate targeted therapies. The new approval was based ...